Table 3.
Crude and adjusted odds ratios for AED type and maternal epilepsy type
| Group | Total | NDDs | No NDDs | Incidence Rate (%) | Unadjusted Odds Ratio | Adjusted Odds Ratio*(95% CI) | p-value |
|---|---|---|---|---|---|---|---|
| Control | 214 | 4 | 210 | 1.87 | Reference Group | Reference Group | - |
| No Medication | 26 | 0 | 26 | 0.00 | - | - | - |
| Valproate | 50 | 6 | 44 | 12.00 | 7.16 | 6.05 (1.65, 24.53) | 0.007 |
| CBZ | 50 | 1 | 49 | 2.00 | 1.07 | 1.09 (0.06, 7.39) | 0.9 |
| LTG | 30 | 2 | 28 | 6.67 | 3.75 | 4.06 (0.55, 22.20) | 0.1 |
| Other Monotherapy | 14 | 2 | 12 | 14.29 | 8.75 | 8.17 (1.09, 49.40) | 0.02 |
| Polytherapy with VPA | 20 | 3 | 17 | 15.00 | 9.26 | 9.97 (1.82, 49.40) | 0.005 |
| Other Polytherapy | 11 | 1 | 10 | 9.09 | 5.25 | 4.95 (0.25, 40.45) | 0.2 |
|
| |||||||
| Focal | 108 | 9 | 99 | 8.33 | 4.77 | 4.76 (1.42, 15.94) | 0.01 |
| Idiopathic Generalised | 65 | 4 | 61 | 6.15 | 3.44 | 3.15 (0.76, 13.09) | 0.1 |
| Unclassified | 28 | 2 | 26 | 7.14 | 4.04 | 3.74 (0.65, 21.67) | 0.1 |
*
separate regression models were created for AED and maternal epilepsy type regressions due to the limited numbers of cases per drug by maternal epilepsy type.